Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1685-1693
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1685
Table 4 Comparison of the changes after administration of tolvaptan (effective vs ineffective with tolvaptan)
| Effective (n = 38) | Ineffective (n = 22) | P | |
| 1Bodyweight | 3.6 (2.1-4.7) | 0.2 (0.1-0.8) | < 0.01 |
| 24 h urine volume (mL) | 2154 (1448-2516) | 1352 (871-1675) | < 0.01 |
| 24 h water intake (mL) | 1238 (800-1429) | 1235 (1000-1463) | 0.96 |
| Pre-urine osmolality (OSM) | 445 (411-485) | 417 (335-495) | 0.42 |
| Time to achieve the minimum urine osmolality (d) | 7 (3-9) | 4 (1-6) | 0.02 |
| The minimum urine osmolality (OSM) | 251 (213-288) | 313 (256-359) | < 0.01 |
| Pre-post-urine osmolality rate (%) | 58 (51-69) | 78 (66-90) | < 0.01 |
- Citation: Ohki T, Sato K, Yamada T, Yamagami M, Ito D, Kawanishi K, Kojima K, Seki M, Toda N, Tagawa K. Efficacy of tolvaptan in patients with refractory ascites in a clinical setting. World J Hepatol 2015; 7(12): 1685-1693
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1685.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1685